You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement
ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In

Vol. 157 No. 22, 8 DECEMBER 1997 TABLE OF CONTENTS
  Online Only
 • Online First Table of
Contents
ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (147)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Trreatment With Alendronate Prevents Fractures in Women at Highest Risk

Results From the Fracture Intervention Trial

Kristine E. Ensrud, MD, MPH; Dennis M. Black, PhD; Lisa Palermo, MS; Douglas C. Bauer, MD; Elizabeth Barrett-Connor, MD; Sara A. Quandt, PhD; Desmond E. Thompson, PhD; David B. Karpf, MD

Arch Intern Med. 1997;157(22):2617-2624.


Abstract


Background
The efficacy of antiresorptive therapy in preventing fractures in women at highest fracture risk, such as very elderly women or those with severe osteoporosis, is uncertain.

Participants and Methods
Using data from a doubleblind, randomized, placebo-controlled clinical trial that enrolled 2027 postmenopausal women aged 55 to 81 years with low femoral neck bone mineral density (BMD) and existing vertebral fractures, we examined the consistency of the effect of treatment with alendronate sodium in preventing fractures within a priori-specified risk subgroups defined at baseline by age, bone density, number of preexisting vertebral fractures, and history of postmenopausal fracture. The women were randomized to oral administration of alendronate or placebo and followed up for an average of 2.9 years. The initial dose of alendronate sodium was 5 mg/d; the dosage was increased from 5 to 10 mg/d at 24 months. New vertebral fractures, the primary end point of this arm of the trial, were defined by morphometry as a decrease of 20% and at least 4 mm in any vertebral height between baseline and a follow-up radiograph at 36 months. Incident clinical fractures, the secondary end point, included nonspine and clinical (symptomatic) vertebral fractures. All clinical fractures were confirmed with x-ray film reports or, in the case of clinical vertebral fractures, x-ray films.

Results
Overall, there was a 47% significant reduction in risk of new vertebral fractures in the alendronate group compared with the placebo group. The reduction in risk of new vertebral fracture was consistent across fracture risk categories including age (relative risk [RR], 0.49 in women <75 years compared with 0.62 in those ≥75 years), BMD (RR, 0.54 in women with a femoral neck BMD <0.59 g/cm2 [median] compared with 0.53 in those with a BMD ≥0.59 g/cm2), and number of preexisting vertebral fractures (RR, 0.58 in women with 1 vertebral fracture compared with 0.52 in those with ≥2). The overall significant 28% reduction in risk of incident clinical fractures in the alendronate group compared with the placebo group was also observed within these subgroups. Compared with the number of lower-risk women, a similar or smaller number of high-risk women needed to be treated to prevent 1 fracture. For example, 8 women aged 75 years or older compared with 9 women younger than 75 years, or 4 women with 2 or more existing vertebral fractures compared with 16 women with 1 existing vertebral fracture, needed to be treated with alendronate for 5 years to prevent 1 new vertebral fracture.

Conclusions
Alendronate effectively reduces fracture risk in postmenopausal women with vertebral fractures and low BMD, including those women at highest risk because of advanced age or severe osteoporosis. Since the risk reductions observed with alendronate treatment were consistent within fracture risk categories, more fractures were prevented by treating women at highest risk.

Arch Intern Med. 1997;157:2617-26244



Author Affiliations


The affiliations of the authors appear in the acknowledgment section at the end of the article For a complete listing of the Fracture Intervention Trial Research Group, see the box on page 2623.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: A cause for concern?
Yoon et al.
J Bone Joint Surg Br 2011;93-B:1289-1295.
ABSTRACT | FULL TEXT  

Effects of Risedronate and Low-Dose Transdermal Testosterone on Bone Mineral Density in Women with Anorexia Nervosa: A Randomized, Placebo-Controlled Study
Miller et al.
J. Clin. Endocrinol. Metab. 2011;96:2081-2088.
ABSTRACT | FULL TEXT  

Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density
Eastell et al.
J. Clin. Endocrinol. Metab. 2009;94:3215-3225.
ABSTRACT | FULL TEXT  

Americans are not meeting current calcium recommendations
Ma et al.
Am J Clin Nutr 2007;85:1361-1366.
ABSTRACT | FULL TEXT  

Bisphosphonate Therapy: To Stop or Not to Stop?
McClung
IBMS BoneKEy 2007;4:78-82.
FULL TEXT  

Fatalities and Injuries From Falls Among Older Adults--United States, 1993-2003 and 2001-2005
JAMA 2007;297:32-33.
FULL TEXT  

Validation of a 4-Item Score Predicting Hip Fracture and Mortality Risk Among Elderly Women
Albertsson et al.
Ann Fam Med 2007;5:48-56.
ABSTRACT | FULL TEXT  

Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
Hodsman et al.
Endocr Rev 2005;26:688-703.
ABSTRACT | FULL TEXT  

A Controlled Trial To Increase Detection and Treatment of Osteoporosis in Older Patients with a Wrist Fracture
Majumdar et al.
ANN INTERN MED 2004;141:366-373.
ABSTRACT | FULL TEXT  

National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003
Stafford et al.
Arch Intern Med 2004;164:1525-1530.
ABSTRACT | FULL TEXT  

Principles of Diagnosing and Managing Postmenopausal Osteoporosis for the Podiatric Physician
McGarry and Cyr
J. Am. Podiatr. Med. Assoc. 2004;94:187-193.
ABSTRACT | FULL TEXT  

OSTEOPOROSIS: TRANSLATING RESEARCH INTO CLINICAL PRACTICE
Gordon
The Gerontologist 2003;43:939-944.
FULL TEXT  

Low Frequency of Treatment of Osteoporosis Among Postmenopausal Women Following a Fracture
Andrade et al.
Arch Intern Med 2003;163:2052-2057.
ABSTRACT | FULL TEXT  

Treatment of postmenopausal osteoporosis
Cranney
BMJ 2003;327:355-356.
FULL TEXT  

Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment
Eichner et al.
The Annals of Pharmacotherapy 2003;37:711-724.
ABSTRACT | FULL TEXT  

Screening for Postmenopausal Osteoporosis
Nelson
ANN INTERN MED 2003;138:689-690.
FULL TEXT  

Internal Fracture Fixation in Patients With Osteoporosis
Cornell
J Am Acad Orthop Surg 2003;11:109-119.
ABSTRACT | FULL TEXT  

Undertreatment of Osteoporosis in Men With Hip Fracture
Kiebzak et al.
Arch Intern Med 2002;162:2217-2222.
ABSTRACT | FULL TEXT  

Alendronate Increases Bone Mass and Reduces Bone Markers in Postmenopausal African-American Women
Bell et al.
J. Clin. Endocrinol. Metab. 2002;87:2792-2797.
ABSTRACT | FULL TEXT  

Osteoporosis Intervention Following Distal Forearm Fractures: A Missed Opportunity?
Cuddihy et al.
Arch Intern Med 2002;162:421-426.
ABSTRACT | FULL TEXT  

Quality Indicators for the Management of Osteoporosis in Vulnerable Elders
Grossman and MacLean
ANN INTERN MED 2001;135:722-730.
FULL TEXT  

Physical activity to prevent falls in older people: time to intervene in high risk groups using falls as an outcome
Khan et al.
Br. J. Sports. Med. 2001;35:144-145.
FULL TEXT  

Recent advances: Geriatric
BMJ 2001;322:86-89.
FULL TEXT  

Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black et al.
J. Clin. Endocrinol. Metab. 2000;85:4118-4124.
ABSTRACT | FULL TEXT  

Editorial: Facets of Femoral Fracture
Perry
J Gerontol A Biol Sci Med Sci 2000;55:M487-M488.
FULL TEXT  

Benefits of Screening for Latent Mycobacterium tuberculosis Infection
Rose
Arch Intern Med 2000;160:1513-1521.
ABSTRACT | FULL TEXT  

Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trial
Lindsay et al.
J. Clin. Endocrinol. Metab. 1999;84:3076-3081.
ABSTRACT | FULL TEXT  

Alternatives to the Use of Estrogen in Postmenopausal Women
Pinkerton and Santen
Endocr Rev 1999;20:308-320.
ABSTRACT | FULL TEXT  

Alendronate reduced new fractures in postmenopausal women who had low bone-mineral density and existing vertebral fractures
Evid. Based Med. 1998;3:119-119.
 

Early Prevention vs Late Treatment for Osteoporosis
Maricic
Arch Intern Med 1997;157:2545-2546.
ABSTRACT  




HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.